Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Annexon Inc

Healthcare US ANNX

5.28USD
0.24(4.76%)

Last update at 2026-06-23T20:27:00Z

Day Range

4.955.39
LowHigh

52 Week Range

1.607.18
LowHigh

Fundamentals

  • Previous Close 5.04
  • Market Cap994.94M
  • Volume5844600
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-214.24099M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.34

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -206.69000M -138.20000M -134.23700M -141.94700M -130.32300M
Minority interest - - - - -
Net income -206.69000M -138.20000M -134.23700M -138.29500M -127.79200M
Selling general administrative 31.71M 34.62M 28.02M 33.10M 30.65M
Selling and marketing expenses - - 3.27M - -
Gross profit -3.68600M -3.45400M -3.26700M - -
Reconciled depreciation 2.17M 2.15M 2.14M 2.11M 2.14M
Ebit -216.40700M -138.20000M -143.72300M -147.70500M -132.85400M
Ebitda -213.75700M -134.74600M -141.57500M -145.59900M -130.71300M
Depreciation and amortization 2.65M 3.45M 2.15M 2.11M 2.14M
Non operating income net other - - - - -
Operating income -216.40700M -154.07300M -143.72300M -145.59900M -130.71300M
Other operating expenses 216.41M 154.07M 143.72M 145.60M 130.71M
Interest expense - - - 3.65M 2.14M
Tax provision - - - - 0.00000M
Interest income 9.72M 15.87M 9.68M 3.65M 0.39M
Net interest income 9.72M 15.87M 9.68M 3.65M 0.39M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - -3.65200M -2.53100M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 212.72M 150.62M 143.72M 145.60M 130.71M
Cost of revenue 3.69M 3.45M 3.27M - -
Total other income expense net 9.72M 15.87M 9.49M 3.65M 0.39M
Discontinued operations - - - - -
Net income from continuing ops -206.69000M -138.20000M -140.72900M -145.59900M -130.71300M
Net income applicable to common shares - - - -141.94700M -130.32300M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 277.57M 350.07M 297.67M 285.10M 287.04M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 3.85M 4.44M 4.14M 5.44M 4.98M
Total liab 65.92M 56.97M 47.12M 53.90M 55.13M
Total stockholder equity 211.65M 293.11M 250.56M 231.19M 231.91M
Deferred long term liab - - - - -
Other current liab 24.79M 17.57M 10.28M 13.63M 0.14M
Common stock 0.15M 0.11M 0.08M 0.05M 0.04M
Capital stock 0.15M 0.11M 0.08M 0.05M 0.04M
Retained earnings -917.38900M -710.69900M -572.49900M -438.26200M -296.31500M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.00000M 1.03M 1.17M
Cash 162.05M 49.50M 225.11M 140.02M 74.84M
Cash and equivalents - - - - -
Total current liabilities 42.63M 30.51M 17.93M 22.36M 21.74M
Current deferred revenue - - - - 9.25M
Net debt -135.85000M -20.52600M -193.75500M -107.16200M -40.25400M
Short term debt 2.91M 2.52M 2.17M 1.32M 1.20M
Short long term debt - - - - -
Short long term debt total 26.20M 28.97M 31.36M 32.86M 34.59M
Other stockholder equity 1128.92M 1003.68M 823.03M 669.78M 528.37M
Property plant equipment - - - 16.84M 38.18M
Total current assets 242.19M 316.46M 263.86M 248.10M 247.69M
Long term investments - - - - -
Net tangible assets - - - 231.19M 231.91M
Short term investments 76.29M 262.52M 34.61M 102.64M 167.87M
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 14.93M 10.43M 5.49M 7.42M 11.15M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.02900M 0.01000M -0.05200M -0.37200M -0.18000M
Additional paid in capital - - - - -
Common stock total equity - - - 0.05M 0.04M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -438.26200M -296.31500M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 9.58M 4.27M 1.03M 1.03M 1.17M
Deferred long term asset charges - - - - -
Non current assets total 35.38M 33.61M 33.81M 37.00M 39.35M
Capital lease obligations 26.20M 28.97M 31.36M 32.86M 34.59M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 190.19M -218.79700M 29.27M 64.97M -86.58200M
Change to liabilities - - - 5.93M 3.86M
Total cashflows from investing activities 190.05M -218.79700M 70.70M 58.44M -88.23600M
Net borrowings - - - - -
Total cash from financing activities 108.86M 161.21M 135.52M 122.91M 1.79M
Change to operating activities - - - 4.03M -0.57500M
Net income -206.69000M -138.20000M -134.23700M -141.94700M -130.32300M
Change in cash 112.55M -175.61200M 85.09M 65.04M -192.55600M
Begin period cash flow 50.53M 226.14M 141.05M 76.01M 268.56M
End period cash flow 163.08M 50.53M 226.14M 141.05M 76.01M
Total cash from operating activities -186.35600M -118.00600M -121.14200M -116.30900M -106.11000M
Issuance of capital stock 109.56M 161.87M 17.55M 130.48M 0.00000M
Depreciation 2.17M 2.15M 2.15M 2.11M 2.14M
Other cashflows from investing activities - - - - -
Dividends paid 1.86M - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - 121.40M 1.79M
Other cashflows from financing activities 0.24M -0.66500M 0.01M -7.56800M 1.79M
Change to netincome - - - 18.52M 18.79M
Capital expenditures 0.14M 0.01M 0.19M 6.53M 1.65M
Change receivables - - - - -
Cash flows other operating - - - -0.98900M -0.21400M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 65.04M -192.55100M
Change in working capital 4.23M 6.36M -5.80500M 3.74M 3.28M
Stock based compensation 16.42M 19.43M 18.18M 18.52M 16.26M
Other non cash items -2.48500M -7.75000M -1.43100M 1.28M 1.27M
Free cash flow -186.49300M -118.02100M -121.33500M -122.83500M -107.76400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ANNX
Annexon Inc		 0.24 4.76% 5.28 - - - 4.88 -2.4694
NVO
Novo Nordisk A/S		 1.54 3.36% 47.42 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.63 0.35% 468.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.53 0.90% 618.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Annexon Inc

1400 Sierra Point Parkway, Brisbane, CA, United States, 94005

Key Executives

Name Title Year Born
Mr. Douglas Love J.D., Esq. CEO, Pres & Director 1968
Dr. Larry C. Mattheakis Ph.D. Exec. VP & Chief Scientific Officer 1957
Dr. Ted Yednock Ph.D. Exec. VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board 1958
Dr. Arnon Rosenthal Ph.D. Founder 1956
Ms. Jennifer Lew Exec. VP & CFO 1973
Miriam Mason Sr. VP of Corp. Communications NA
Mr. Michael Overdorf M.B.A. Exec. VP & Chief Bus. Officer 1970
Henk-Andre Kroon M.D. Sr. VP of Translational Medicine NA
Mirella Villa Del Toro Sec. NA
Mr. Douglas Love Esq., J.D. CEO, President & Director 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.